Trulance (plecanatide) and Linzess (linaclotide) are brand-name prescription medications. They’re approved by the Food and Drug Administration (FDA) to treat certain types of constipation. Trulance ...

Trulance (plecanatide) is a prescription oral tablet used in adults to treat constipation due to certain conditions. This drug isn’t known to interact with other medications, but it can interact with ...

Trulance (plecanatide) is a brand-name prescription medication. The Food and Drug Administration (FDA) has approved it to treat certain forms of constipation in adults. As with all medications, the ...

Trulance and Linzess are prescription medications for adults that treat chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C). They have similar safety and ...

Please provide your email address to receive an email when new articles are posted on . CHICAGO — Trulance safely and effectively improved symptoms in patients with constipation-predominant irritable ...

Ahead of the fourth quarter showcase from Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) anticipated March 7 th, first comes a PDUFA date of FDA judgment for Trulance. As approval waits in the wings ...

New York City-based Synergy Pharmaceuticals submitted a supplemental New Drug Application for Trulance. Here’s what you should know. 1. Trulance was FDA approved in adults with chronic idiopathic ...

Synergy Pharmaceuticals has received FDA approval for Trulance (plecanatide), a treatment for adult chronic idiopathic constipation. Chronic idiopathic constipation describes patients who experience ...

Please provide your email address to receive an email when new articles are posted on . At 12 weeks, significant improvements in overall PAC-QoL and IBS-QoL scores favored plecanatide over placebo.

Synergy Pharmaceuticals Inc SGYP presented positive results from its Phase 3 study of plecanatide for the treatment of irritable bowel syndrome with constipation (IBS-C). In two large studies, Synergy ...

Synergy Pharmaceuticals Inc. SGYP announced that the FDA has approved one of its lead pipeline candidates, Trulance (plecanatide), for the treatment of adults suffering from chronic idiopathic ...

The chronic idiopathic constipation (CIC) market has a new entrant. This was occasioned by the FDA’s approval of Trulance from Synergy Pharmaceuticals Inc (NASDAQ:SGYP). The agency’s move triggers ...